Abbott To Cut Rx Development Costs In Half By Increasing Candidate Attrition
Abbott believes it can cut the cost of drug development in half by increasing the rate of attrition in the discovery phase, the company said Feb. 9 at a drug development summit sponsored by R&D Directions in Phoenix
You may also be interested in...
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix
FDA is understood to be considering whether legislation could be useful to help promote translational research for pharmaceuticals
Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York